How to Check Vijaypd Ceutical IPO Allotment Status?

Vijaypd Ceutical Limited is engaged in distribution of pharmaceutical products and consumer goods offering comprehensive range of services, incorporated in October 1971, acting as representatives, dealers, agents, stockists, suppliers, traders, and packers serving pharmaceutical and wellness industries as well as FMCG market, offering products including medicines in various forms such as injections, tablets, capsules, ointments, suppositories, ophthalmic preparations, liquid oral products, vitamins, hormones, enzymes, wellness tonics, serums, diagnostic test kits, personal care items including soaps, sanitizers, baby care products, ayurvedic products, cosmetics, food products, dental products, and crude drugs, serving over 2,109 pharmacies, clinics, and nursing homes across four districts covering 20 locations as of March 31, 2025, maintaining distribution network connecting with over 170 healthcare product manufacturers providing access to more than 19,000 SKUs, holding FDA, FSSAI, and BMC certifications with streamlined supply chain management and experienced management team.

The Vijaypd Ceutical IPO came with a total issue size of ₹19.25 crore, comprising entirely a fresh issue of 0.55 crore shares aggregating to ₹19.25 crore. The IPO opened on September 29, 2025, and closed on October 1, 2025. The allotment for the Vijaypd Ceutical IPO is expected to be finalized on Friday, October 3, 2025. The Vijaypd Ceutical IPO share price was fixed at ₹35 per share.

Don’t Miss Out on the Next Big IPO – Invest With Just a Few Clicks!

Open Account Now

Steps to Check Vijaypd Ceutical IPO Allotment Status on Registrar Site

• Visit the Kfin Technologies Ltd. website
• Select "Vijaypd Ceutical" from the dropdown menu on the allotment status page
• Enter your PAN ID, Demat Account Number, or Application Number in the designated field
• Complete the captcha verification process and click on the "Submit" button to view your allotment status

Steps to Check Vijaypd Ceutical IPO Allotment Status on NSE

• Navigate to the NSE SME IPO Allotment Status Page
• Select the issue type: equity/debt
• Choose "Vijaypd Ceutical" from the list of active IPOs in the dropdown menu
• Input your Application Number and PAN ID in the required fields
• Verify the captcha and click "Search" to check your allotment status

Vijaypd Ceutical IPO Subscription Status

Vijaypd Ceutical IPO received weak investor interest, being subscribed 1.37 times overall. The subscription showed poor confidence with weak retail participation and modest NII interest. Here is a category-wise breakdown of the subscription as of 5:14:16 PM on October 1, 2025:

• Non-Institutional Investors (NII): 1.86 times.
• Retail Investors: 0.89 times.

Vijaypd Ceutical IPO Share Price and Investment Details

The Vijaypd Ceutical IPO stock price was fixed at ₹35 per share with a minimum lot size of 4,000 shares. The minimum investment required for retail investors was ₹2,80,000 for 2 lots (8,000 shares). The issue included 2,84,000 shares allocated to market maker raising ₹0.99 crore. Given the weak subscription response of 1.37 times overall, with particularly poor retail participation at 0.89 times and modest NII interest at 1.86 times, the Vijaypd Ceutical IPO share price is expected to list with flat to negative premium.

Utilisation of IPO Proceeds

The funds raised through the IPO will be utilised as follows:

• Capital expenditure for construction of pharmaceutical API/intermediates and chemicals manufacturing plant: ₹10.83 crore.
• Repayment/prepayment of borrowings: ₹5.10 crore.
• General corporate purposes: ₹0.74 crore.

Business Overview

Vijaypd Ceutical Limited operates with strengthened market position through long-term client relationships, comprehensive product portfolio spanning over 19,000 SKUs across pharmaceuticals and FMCG segments, streamlined supply chain management connecting with 170+ manufacturers, and experienced management team with proven execution capabilities while demonstrating exceptional financial performance with 98% revenue increase and 191% PAT rise between FY24-FY25, maintaining healthy financial metrics with 28.91% ROE and moderate debt-equity ratio of 0.68 though the boosted performance for FY25 raises sustainability questions. The company, operating since 1971, enjoys established positioning in pharmaceutical distribution segment with regulatory certifications and extensive distribution network, positioned to benefit from India's growing healthcare and FMCG sectors.